Cargando…

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates

Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the human population. Resistance to carbapenems is o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sękowska, Alicja, Grabowska, Marta, Bogiel, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057464/
https://www.ncbi.nlm.nih.gov/pubmed/36984519
http://dx.doi.org/10.3390/medicina59030518
_version_ 1785016373808726016
author Sękowska, Alicja
Grabowska, Marta
Bogiel, Tomasz
author_facet Sękowska, Alicja
Grabowska, Marta
Bogiel, Tomasz
author_sort Sękowska, Alicja
collection PubMed
description Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the human population. Resistance to carbapenems is one of the most important antimicrobial resistance mechanisms amongst them. The aim of this study was to evaluate ceftolozane–tazobactam in vitro activity against carbapenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae clinical strains. Information on the antimicrobial activity of this antimicrobial against Gram-negative rods was also supplemented with a brief review of the relevant literature. Methods: The research involved 316 strains of Gram-negative rods: P. aeruginosa—206 and K. pneumoniae—110. Results: Of the tested strains, 86.0% P. aeruginosa and 30.0% K. pneumoniae remained susceptible to ceftolozane–tazobactam. Conclusions: Therefore, ceftolozane–tazobactam might be a good option in the treatment of infections caused by carbapenem-resistant P. aeruginosa strains, including those in ICU patients. Meanwhile, due to dissemination of ESBLs among K. pneumoniae strains, infections with this etiology should not be treated with the ceftolozane–tazobactam combination.
format Online
Article
Text
id pubmed-10057464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100574642023-03-30 Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates Sękowska, Alicja Grabowska, Marta Bogiel, Tomasz Medicina (Kaunas) Article Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the human population. Resistance to carbapenems is one of the most important antimicrobial resistance mechanisms amongst them. The aim of this study was to evaluate ceftolozane–tazobactam in vitro activity against carbapenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae clinical strains. Information on the antimicrobial activity of this antimicrobial against Gram-negative rods was also supplemented with a brief review of the relevant literature. Methods: The research involved 316 strains of Gram-negative rods: P. aeruginosa—206 and K. pneumoniae—110. Results: Of the tested strains, 86.0% P. aeruginosa and 30.0% K. pneumoniae remained susceptible to ceftolozane–tazobactam. Conclusions: Therefore, ceftolozane–tazobactam might be a good option in the treatment of infections caused by carbapenem-resistant P. aeruginosa strains, including those in ICU patients. Meanwhile, due to dissemination of ESBLs among K. pneumoniae strains, infections with this etiology should not be treated with the ceftolozane–tazobactam combination. MDPI 2023-03-07 /pmc/articles/PMC10057464/ /pubmed/36984519 http://dx.doi.org/10.3390/medicina59030518 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sękowska, Alicja
Grabowska, Marta
Bogiel, Tomasz
Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title_full Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title_fullStr Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title_full_unstemmed Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title_short Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
title_sort satisfactory in vitro activity of ceftolozane–tazobactam against carbapenem-resistant pseudomonas aeruginosa but not against klebsiella pneumoniae isolates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057464/
https://www.ncbi.nlm.nih.gov/pubmed/36984519
http://dx.doi.org/10.3390/medicina59030518
work_keys_str_mv AT sekowskaalicja satisfactoryinvitroactivityofceftolozanetazobactamagainstcarbapenemresistantpseudomonasaeruginosabutnotagainstklebsiellapneumoniaeisolates
AT grabowskamarta satisfactoryinvitroactivityofceftolozanetazobactamagainstcarbapenemresistantpseudomonasaeruginosabutnotagainstklebsiellapneumoniaeisolates
AT bogieltomasz satisfactoryinvitroactivityofceftolozanetazobactamagainstcarbapenemresistantpseudomonasaeruginosabutnotagainstklebsiellapneumoniaeisolates